Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
about
Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.The use of isotopes in the determination of absolute bioavailability of drugs in humans.Chemical modification and formulation approaches to elevated drug transport across cell membranes.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.Toward a new age of cellular pharmacokinetics in drug discovery.The role of diet on the clinical pharmacology of oral antineoplastic agents.Molecular buckets: cyclodextrins for oral cancer therapy.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Planar bioadhesive microdevices: a new technology for oral drug delivery.The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature.In vitro effects of standardized extract of Bacopa monniera and its five individual active constituents on human P-glycoprotein activity.Substrate-dependent effects of human ABCB1 coding polymorphismsFuture Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.Site of reactivity models predict molecular reactivity of diverse chemicals with glutathione.Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view.National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration.
P2860
Q33408664-C1FD28C9-49FB-4C5F-B32E-4FFD95CE88CEQ34550493-73071C52-CA35-45C6-8834-3576A6C81534Q36527751-6CDAC568-D2E4-492C-9ECF-74FC5783BCB2Q36960535-EFC4349E-8E0D-4A1E-930E-6C1A76F84818Q37369825-645AF26D-0026-46F8-AA10-48D95ECEB367Q37851981-90C7771B-9F27-40A8-8006-98B40501C25BQ37907103-85327A79-7ADA-4301-A770-C6A96D090FBEQ38029632-2B261C03-345F-4B73-8010-9A6677CFAA38Q38082728-39F50CCE-7983-4863-8095-848BB6711900Q38248999-09A6AC0E-24AC-4129-9387-AB75700F12F5Q38282454-9D1FC849-ACFB-4F67-B01E-0D2717B786BBQ38887833-5A9166F3-E075-4B84-B21A-D8C9498C8635Q40011132-EF02CEB3-91C0-41A2-BDE4-F4D29ECB60E4Q40031757-C1AD6686-DB77-4E6F-84EF-13D26D8AD415Q41289680-3510F876-EC15-45CE-AE25-35DA427DCD46Q43995286-695A52AF-297B-4D94-BAF7-9969412E361DQ48115704-4DE562C9-5E51-45D1-AC1C-25B3513E0CE4Q48296939-39E01C9A-8321-4570-ACF3-71ED3772B261Q49179365-73EA1641-EFDE-4B1D-8150-F882124E8F4BQ51756208-268555B7-D1A8-448A-A367-696ACB78559D
P2860
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Modulation of oral drug bioava ...... sm to therapeutic application.
@ast
Modulation of oral drug bioava ...... sm to therapeutic application.
@en
type
label
Modulation of oral drug bioava ...... sm to therapeutic application.
@ast
Modulation of oral drug bioava ...... sm to therapeutic application.
@en
prefLabel
Modulation of oral drug bioava ...... sm to therapeutic application.
@ast
Modulation of oral drug bioava ...... sm to therapeutic application.
@en
P2093
P2860
P356
P1433
P1476
Modulation of oral drug bioava ...... sm to therapeutic application.
@en
P2093
Isa E L M Kuppens
J H Beijnen
J H M Schellens
P Breedveld
P2860
P304
P356
10.1081/CNV-58823
P577
2005-01-01T00:00:00Z